Adagene (NASDAQ:ADAG) CEO Purchases 20,290 Shares

Adagene Inc. Sponsored ADR (NASDAQ:ADAG) CEO Peter Luo bought 20,290 shares of the business’s stock in a transaction on Wednesday, September 16th. The stock was bought at an average price of $3.15 per share, for a total transaction of $63,913.50. Following the completion of the purchase, the chief executive officer directly owned 88,535 shares of the company’s stock, valued at $278,885.25. The trade was a 29.73% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Peter Luo also recently made the following trade(s):

• On Wednesday, August 5th, Peter Luo bought 279 shares of Adagene stock. The shares were acquired at an average cost of $3.65 per share, for a total transaction of $1,018.35.
• On Tuesday, August 4th, Peter Luo purchased 22,966 shares of Adagene stock. The shares were bought at an average price of $3.65 per share, for a total transaction of $83,825.90.

Adagene Stock Performance

Shares of Adagene stock opened at $3.17 on Thursday. Adagene Inc. Sponsored ADR has a fifty-two week low of $1.30 and a fifty-two week high of $4.85. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.07 and a current ratio of 5.02. The business has a fifty day simple moving average of $3.69 and a 200-day simple moving average of $3.72.

Institutional Investors Weigh In On Adagene

A hedge fund recently bought a new position in Adagene stock. Renaissance Technologies LLC bought a new stake in shares of Adagene Inc. Sponsored ADR (NASDAQ:ADAG) during the 1st quarter, according to its most recent filing with the SEC. The fund bought 34,533 shares of the company’s stock, valued at approximately $135,000. Renaissance Technologies LLC owned approximately 0.07% of Adagene as of its most recent filing with the SEC. 9.51% of the stock is owned by institutional investors.

Key Stories Impacting Adagene

Here are the key news stories impacting Adagene this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and $7 price target. The target implies meaningful upside from recent trading levels and provides a positive signal for investor sentiment. Adagene Earns Buy Rating from HC Wainwright
• Positive Sentiment: HC Wainwright raised its projected loss estimates for fiscal 2027 through fiscal 2030, forecasting losses of $0.42, $0.70, $1.07 and $0.87 per share, respectively, compared with previously wider losses. The revisions suggest improved expectations for Adagene’s longer-term financial performance. Adagene analyst estimates
• Positive Sentiment: At the H.C. Wainwright conference, Adagene highlighted its high-dose CTLA-4 therapy, keeping investor attention focused on the company’s antibody-immunotherapy pipeline and potential clinical value. Adagene at H.C. Wainwright conference
• Neutral Sentiment: Adagene also presented at Morgan Stanley’s Global Healthcare Conference, offering additional visibility for its development programs but no clearly disclosed near-term commercial catalyst. Adagene Morgan Stanley conference transcript
• Negative Sentiment: HC Wainwright lowered its fiscal 2026 loss forecast to $0.43 per share from $0.37, indicating weaker near-term earnings expectations. Separately, another report cited a 10.44% reduction in a price target to $10.50, which could temper enthusiasm despite the bullish H.C. Wainwright view. Adagene price target reduced

Analysts Set New Price Targets

Several brokerages have commented on ADAG. Guggenheim reiterated a “buy” rating and set a $10.00 price target on shares of Adagene in a report on Tuesday, July 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Adagene in a report on Friday, July 17th. Chardan Capital assumed coverage on Adagene in a research note on Thursday, September 10th. They issued a “buy” rating and a $9.00 price objective on the stock. Finally, HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Adagene in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Adagene has a consensus rating of “Moderate Buy” and a consensus target price of $8.67.

Adagene Company Profile

Adagene Inc is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based medicines for cancer and other serious diseases. The company combines computational antibody-design capabilities with laboratory-based discovery and development platforms to create differentiated therapeutic candidates.

Adagene’s technology portfolio includes its SAFEbody platform, which is designed to mask antibody binding sites until the medicines reach the tumor microenvironment, potentially improving tumor selectivity and reducing activity in healthy tissue.